Abstracts Archive - Page 2411 of 2425 - ACR Meeting Abstracts

Abstract Number: 156 • 2012 ACR/ARHP Annual Meeting
Menopause and the Prevalence of Gout and Hyperuricemia: An Age-Matched Case Control Study
Eswar Krishnan¹ and Mihoko Bennett², ¹Medicine, Standford University, Palo Alto, CA, ²Pediatrics, Stanford University, Palo Alto, CA
Background/Purpose: Among women, the prevalence of gouty arthritis (gout) and hyperuricemia (serum urate>6.0 mg/dL) increases steeply after the age 60. This increase has been attributed…
Abstract Number: 157 • 2012 ACR/ARHP Annual Meeting
Prevalence of Gout Among Adults with Chronic Kidney Disease in the United States, 2009-10
Eswar Krishnan, Medicine, Standford University, Palo Alto, CA
Background/Purpose: The kidney is a major route of clearance of uric acid, a product of purine metabolism. The links between kidney disease, hyperuricemia, and gout…
Abstract Number: 158 • 2012 ACR/ARHP Annual Meeting
Focus Groups Reveal Knowledge Gaps in Patients with Gout-A Qualitative Study
Puja Khanna¹, Veronica Berrocal², Tonya Hays³, Daniel J. Clauw⁴ and David A. Williams⁵, ¹Division of Rheumatology/Dept. of Internal Medicine, University of Michigan, Ann Arbor, MI, ²Department of Biostatistics- School of Public Health, University of Michigan, Ann Arbor, MI, ³Survey Research Center, UCLA, Los Angeles, CA, ⁴Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, ⁵Chronic Pain & Fatigue Rsch Ctr, Univ of MI Hlth System-Lobby M, Ann Arbor, MI
Background/Purpose: Gout is the most treatable arthritis in the Western World and there are effective medications available to treat both acute episodes and chronic gout.…
Abstract Number: 159 • 2012 ACR/ARHP Annual Meeting
Clinical Efficacy Outcomes with up to 3 Years of Pegloticase Treatment for Refractory Chronic Gout
Michael A. Becker¹, Herbert S. B. Baraf², Robert A. Yood³, Aileen M. Dillon⁴, Janitzia Vazquez-Mellado⁵, Faith D. Ottery⁶, Dinesh Khanna⁷ and John S. Sundy⁸, ¹Medicine, University of Chicago, Chicago, IL, ²Arthritis & Rheumatism Associates, Wheaton, MD, ³Reliant Medical Group, Worcester, MA, ⁴Rheumatology Section, Kaiser Foundation Hospital, San Francisco, CA, ⁵Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ⁶Medical Affairs, Savient Pharmaceuticals, Inc., East Brunswick, NJ, ⁷Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁸Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Background/Purpose: Pegloticase, a recombinant modified mammalian uricase conjugated to mPEG, was approved for use in refractory chronic gout in the US in 2010. The Phase…
Abstract Number: 160 • 2012 ACR/ARHP Annual Meeting
Pegloticase Long-Term Safety: Data From the Open-Label Extension Trial
Michael A. Becker¹, Herbert S. B. Baraf², Robert A. Yood³, Aileen M. Dillon⁴, Janitzia Vazquez-Mellado⁵, Faith D. Ottery⁶, Dinesh Khanna⁷ and John S. Sundy⁸, ¹Medicine, University of Chicago, Chicago, IL, ²Arthritis & Rheumatism Associates, Wheaton, MD, ³Reliant Medical Group, Worcester, MA, ⁴Rheumatology Section, Kaiser Foundation Hospital, San Francisco, CA, ⁵Rheumatology, Hospital General de Mexico, Mexico city, Mexico, ⁶Medical Affairs, Savient Pharmaceuticals, Inc., East Brunswick, NJ, ⁷Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁸Duke Clinical Research Institute, Duke University Medical Center, Durham, NC
Background/Purpose: Pegloticase is a recombinant modified mammalian uricase conjugated to mPEG and approved for treatment of refractory chronic gout. Pegloticase safety was evaluated during 2…
Abstract Number: 161 • 2012 ACR/ARHP Annual Meeting
Increased Serum Uric Acid: Consequence or Cause of Increased Cardiovascular Risk
Inger L. Meek¹, Harald E. Vonkeman² and Mart A.F.J. van de Laar³, ¹Rheumatology & Clinical Immunology, Rheumatology Center Twente, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, ²Rheumatology Center Twente, Medisch Spectrum Twente & Twente University, Enschede, Netherlands, ³Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands
Background/Purpose: Reports on cardiovascular (CV) disease in hyperuricemia and gout show conflicting results. Some studies show hyperuricemia to be an independent risk factor for CV…
Abstract Number: 162 • 2012 ACR/ARHP Annual Meeting
Metabolic Syndrome: The Genesis of Nephrolithiasis in Gout Patients
Filipi M. Mello¹, Rafael B. Tomita², Ricardo Fuller³, Marco Antonio G. P. Filho², Thiago B. M. Barros⁴, Leandro L. do Prado², Kristopherson L. Augusto² and Claudia Goldenstein-Schainberg⁵, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Rheumatology Division - University of São Paulo, São Paulo, Brazil, ³Reumatologia, Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Reumatologia Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Reumatologia, Rheumatology Division - University of São Paulo, São Paulo, Brazil
Background/Purpose: Gout patients have a high frequency of metabolic syndrome (MS), a disorder known to be associated with hyperinsulinemia. The latter condition augments proximal tubular…
Abstract Number: 163 • 2012 ACR/ARHP Annual Meeting
Evaluating Allopurinol Therapy and Serum Uric Acid Levels in Medicare Beneficiaries with Gout
Melea Ward¹, Anthony M. Louder², Keith A. Szymanski³ and Leonardo Tamariz⁴, ¹Competitive Health Analytics, Louisville, KY, ²Competitive Health Analytics, Inc., Louisville, KY, ³Takeda Pharmaceuticals America, Inc., Deerfield, IL, ⁴University of Miami, Miami, FL
Background/Purpose: Higher serum uric acid levels in gout patients have been associated with an increased frequency and risk of gout flares and greater subsequent healthcare…
Abstract Number: 164 • 2012 ACR/ARHP Annual Meeting
The Prevalence of Gout in a Large Tertiary Hospital and the Impact of in-Hospital Attacks of Acute Gout On Patient Outcomes and Health Resource Utilisation – a Nested Case-Control Study
John HY Moi¹, Mark Tacey², Carol Roberts³, Caroline Brand², Alexandra Gorelik³ and Sharon Van Doornum², ¹Department of Rheumatology, Department of Medicine (RMH), The Royal Melbourne Hospital, The University of Melbourne, Melbourne, Australia, ²Melbourne EpiCentre, The University of Melbourne, Melbourne, Australia, ³Melbourne EpiCentre, The Royal Melbourne Hospital, Melbourne, Australia
Background/Purpose: Acute gout can develop in hospitalised patients either as a new event or as a recurrence of established disease. To date there have been…
Abstract Number: 165 • 2012 ACR/ARHP Annual Meeting
Colchicine Is Associated with a Decreased Rate of Myocardial Infarction in Gout Patients: Interim Results From a Retrospective Cohort Study
Daria B. Crittenden¹, Cilian J. White¹, Michael DeBerardine¹, Grace Kim², Binita Shah³, Jessica C. Kimmel¹, Rima D. Patel¹, Steven P. Sedlis³, Jeffrey D. Greenberg⁴, Craig T. Tenner⁵, Bruce N. Cronstein¹ and Michael H. Pillinger¹, ¹Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY, ²NYU School of Medicine, Division of Rheumatology, New York, NY, ³NYU School of Medicine, Division of Cardiology, New York, NY, ⁴Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁵Internal Medicine, NYU School of Medicine, Department of Internal Medicine, New York, NY
Background/Purpose: Atherosclerosis is an inflammatory process, but to date no anti-inflammatory agent has definitively been shown to alter cardiovascular (CV) risk. Colchicine is an anti-inflammatory…
Abstract Number: 166 • 2012 ACR/ARHP Annual Meeting
Low-Dose Allopurinol Promotes Greater Serum Urate Lowering in Gout Patients with Chronic Kidney Disease Vs Normal Renal Function
Michael DeBerardine¹, Mark C. Fisher², Robert T. Keenan³, Michael H. Pillinger⁴ and Daria B. Crittenden⁴, ¹NYU School of Medicine, Division of Rheumatology, New York, NY, ²Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Boston, MA, ³Rheumatology, Duke University, Durham, NC, ⁴Internal Medicine, NYU School of Medicine, Division of Rheumatology, New York, NY
Background/Purpose: Patients with chronic kidney disease (CKD) may be at increased risk for allopurinol (ALLO) hypersensitivity, possibly because impaired renal excretion causes accumulation of the…
Abstract Number: 127 • 2012 ACR/ARHP Annual Meeting
Ultrasonographic Evaluation of the Hands of Patients with Primary and Secondary Sjögren´s Syndrome
Cristina Hernández-Díaz¹, Luis M. Amezcua-Guerra², Angélica Vargas², Alberto Lopez-Reyes³ and Carlos Pineda⁴, ¹Musculoskeletal Ultrasound, Instituto Nacional de Rehabilitación, Mexico City, Mexico, ²Rheumatology, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ³Synovial fluid and molecular analysis laboratory, Instituto Nacional de Rehabilitacion, Mexico City, Mexico, ⁴Biomedical Research, Instituto Nacional de Rehabilitacion, Mexico City, Mexico
Background/Purpose: Primary Sjögren’s syndrome (pSS) is an autoimmune disease characterized by lymphocyte infiltration of various exocrine glands, often associated with joint involvement traditionally described as…
Abstract Number: 128 • 2012 ACR/ARHP Annual Meeting
Quantitative Assessment of Synovitis in Patients with Rheumatoid Arthritis Using Fluorescence Optical Imaging
Valentin S. Schäfer¹, Wolfgang Hartung², Patrick Hoffstetter³, Jörn Berger⁴, Martina Müller⁵, Martin Fleck² and Boris P. Ehrenstein², ¹Rheumatology & Clinical Immunology, Asklepios Klinikum Bad Abbach, Bad Abbach, Germany, ²Rheumatology & Clinical Immunology, Asklepios Clinic Bad Abbach, Bad Abbach, Germany, ³Radiology, Asklepios Klinikum Bad Abbach, Bad Abbach, Germany, ⁴mivenion GmbH, Berlin, Germany, ⁵Clinic for Internal Medicine I, University Clinic Regensburg, Regensburg
Background/Purpose: To prospectively evaluate quantitative assessment of indocyanine green (ICG)-enhanced fluorescence optical imaging (FOI) for differentiation of synovitic from non-synovitic joints in patients suffering from…
Abstract Number: 129 • 2012 ACR/ARHP Annual Meeting
Comparison of Automated, Computer-Based Assessment and Visually Assessed Disease Activity Scores in ICG-Enhanced Fluorescence Optical Imaging in Patients with Rheumatic Disorders: A Feasibility Study
Stephanie G. Werner¹, Michael Schirner², Hans-Eckhard Langer³, Mathias Cziumplik², Jörn Berger², Marina Backhaus¹ and Malte Bahner², ¹Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ²mivenion GmbH, Berlin, Germany, ³RHIO (Rheumatology, Immunology, Osteology) Duesseldorf, Duesseldorf, Germany
Background/Purpose: Modern diagnostic imaging technologies including US and MRI become increasingly important in the management of rheumatic joint disorders. Semiquantitative scores, like the RAMRIS or…
Abstract Number: 130 • 2012 ACR/ARHP Annual Meeting
Is Bone Scintigraphy Still Useful to Diagnose Rheumatoid Arthritis After the Appearance of 2010 ACR/EULAR Classification Criteria?
Ji Young Kim¹, Soo-Kyung Cho², Min-Kyung Han², Yun Young Choi¹ and Yoon-Kyoung Sung², ¹Department of Nuclear Medicine, Hanyang University College of Medicine, Seoul, South Korea, ²Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: For many years, the importance of bone scintigraphy to measure inflammation in the joints of patients with RA has been emphasized. Moreover, increased blood…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].